Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII-Reference-Cited by-同舟云学术

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII

Published:2019-08-28 Issue: Volume:2019 Page:1-5
ISSN:2090-6560
Container-title:Case Reports in Hematology
language:en
Short-container-title:Case Reports in Hematology

Author:

Nguyen S.¹²^ORCID,Teh P.²,Zhou J.¹³,Chang E. Y.⁴⁵^ORCID,von Drygalski A.¹³^ORCID

Affiliation:

1. Department of Medicine, University of California San Diego, San Diego, CA, USA

2. Department of Medicine, University of California Riverside, Riverside, CA, USA

3. Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA

4. Radiology Service, VA San Diego Healthcare System, San Diego, CA, USA

5. Department of Radiology, University of California San Diego, San Diego, CA, USA

Abstract

Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products.

Publisher

Hindawi Limited

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

http://downloads.hindawi.com/journals/crihem/2019/9026121.pdf

Reference26 articles.

1. How I manage patients with acquired haemophilia A

2. ACQUIRED HEMOPHILIA

3. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation

4. Long term outcome of patients with acquired haemophilia – A monocentre interim analysis of 82 patients

5. A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor-viii-inhibitor-bypassing-fraction/recombinant-factor-viia;Reactions Weekly;2023-02-11

2. Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline;Haemophilia;2022-03-13

3. Cross‐reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A;Haemophilia;2020-09-30

4. Critical Bleeding in Acquired Hemophilia A: Bypassing Agents or Recombinant Porcine Factor VIII?;Hämostaseologie;2020-09-11

5. Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding;Expert Opinion on Orphan Drugs;2020-03-03